Myrio partners with US schools to advance next-gen T-cell therapies

Australian biotech Myrio Therapeutics has joined forces with the University of Pennsylvania’s Perelman School of Medicine and NYU Langone Health to accelerate the development of next-generation immunotherapies for solid tumors.

The collaboration combines expertise in peptide HLA binder discovery, bispecific T-cell engager development, and cell-based immunotherapy to tackle some of the toughest challenges in oncology. Research will center on three pillars: targeting oncogenic drivers, amplifying innate immune functions, and developing novel chimeric antigen receptor (CAR) architectures able to recognize low-abundance tumor targets.

Myrio chief executive Graeme Wald described the partnership as “a magnificent case of putting the best technologies and people together to develop products for solid tumor treatments.” The parties intend to establish a new company and seek seed funding to move toward clinical development.